Abstract：
OBJECTIVE: This review summarises the shifting paradigms in the treatment of ischemic left ventricular dysfunction, spotlighting the revascularization for ischemic ventricular dysfunction-British cardiovascular intervention society-2 (REVIVED-BCIS2) trial results and its impact on key therapeutic goals: survival, left ventricular function, arrhythmia prevention, quality of life and viability testing.
RESULTS: The REVIVED-BCIS2 trial, and its subsequent sub studies highlighted that (PCI) does not provide additional benefits to optimal medical therapy in terms of improving survival, left ventricular (LV) function, arrhythmic risk or quality of life. Additionally, viability testing did not differentiate patients who could benefit from PCI, although scar burden was found to be a significant predictor of outcome in these patients.
CONCLUSIONS: The outcomes of REVIVED have challenged multiple existing beliefs in the field of ischaemic left ventricular dysfunction management, emphasising the importance of investigating evidence free areas in our practice. Future work, including the STICH3 international consortium of trials, aims to answer some of the remaining unanswered questions.
RESULTS: The REVIVED-BCIS2 trial, and its subsequent sub studies highlighted that (PCI) does not provide additional benefits to optimal medical therapy in terms of improving survival, left ventricular (LV) function, arrhythmic risk or quality of life. Additionally, viability testing did not differentiate patients who could benefit from PCI, although scar burden was found to be a significant predictor of outcome in these patients.
CONCLUSIONS: The outcomes of REVIVED have challenged multiple existing beliefs in the field of ischaemic left ventricular dysfunction management, emphasising the importance of investigating evidence free areas in our practice. Future work, including the STICH3 international consortium of trials, aims to answer some of the remaining unanswered questions.
摘要：
目的：本综述总结了缺血性左心室功能障碍治疗的转变模式，聚焦缺血性心室功能障碍的血运重建-英国心血管介入学会-2（REVIVED-BCIS2）试验结果及其对关键治疗目标的影响：生存，左心室功能,预防心律失常,生活质量和生存能力测试。
结果：REVIVED-BCIS2试验，及其随后的子研究强调，（PCI）在提高生存率方面并没有为最佳药物治疗提供额外的益处，左心室（LV）功能，心律失常风险或生活质量。此外,尽管发现瘢痕负荷是这些患者预后的重要预测因子,但生存能力测试并不能区分可从PCI获益的患者.
结论：REVIVED的结果挑战了缺血性左心室功能障碍管理领域的多种现有信念，强调在我们的实践中调查无证据领域的重要性。未来的工作,包括STICH3国际试验联盟，旨在回答一些剩余的未回答的问题。
结果：REVIVED-BCIS2试验，及其随后的子研究强调，（PCI）在提高生存率方面并没有为最佳药物治疗提供额外的益处，左心室（LV）功能，心律失常风险或生活质量。此外,尽管发现瘢痕负荷是这些患者预后的重要预测因子,但生存能力测试并不能区分可从PCI获益的患者.
结论：REVIVED的结果挑战了缺血性左心室功能障碍管理领域的多种现有信念，强调在我们的实践中调查无证据领域的重要性。未来的工作,包括STICH3国际试验联盟，旨在回答一些剩余的未回答的问题。
